Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7–33

Article  Google Scholar 

Fahad UM (2019) Breast cancer: current perspectives on the disease status. Adv Exp Med Biol 1152:51–64

Article  Google Scholar 

Budh DP, Sapra A (2022) Breast cancer screening. 2022 17. In: StatPearls. Treasure Island (FL): StatPearls Publishing.

Ben Aziz M, Mukhdomi T (2022) Regional anesthesia for breast reconstruction. 2022 19. In: StatPearls. Treasure Island (FL): StatPearls Publishing.

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013

Article  Google Scholar 

Yin L, Duan JJ, Bian XW, Yu SC (2020) Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res 22(1):61

Article  Google Scholar 

Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P et al (2007) Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and End Results database. Cancer 110(4):876–884

Article  Google Scholar 

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429–4434

Article  Google Scholar 

Bergin ART, Loi S (2019) Triple-negative breast cancer: recent treatment advances. F1000Res 8:F1000 Faculty Rev-1342.

Chen Z, Wang X, Li X, Zhou Y, Chen K (2021) Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy. J Int Med Res 49(2):300060521991019

Article  CAS  Google Scholar 

Bjarnason NH, Hitz M, Jorgensen NR, Vestergaard P (2008) Adverse bone effects during pharmacological breast cancer therapy. Acta Oncol 47(4):747–754

Article  CAS  Google Scholar 

Chaudhary LN, Wilkinson KH, Kong A (2018) Triple-negative breast cancer: who should receive neoadjuvant chemotherapy? Surg Oncol Clin N Am 27(1):141–153

Article  Google Scholar 

JabbarzadehKaboli P, Salimian F, Aghapour S, Xiang S, Zhao Q, Li M et al (2020) Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer—a comprehensive review from chemotherapy to immunotherapy. Pharmacol Res 156:104806

Article  CAS  Google Scholar 

Lebert JM, Lester R, Powell E, Seal M, McCarthy J (2018) Advances in the systemic treatment of triple-negative breast cancer. Curr Oncol 25(Suppl 1):S142–S150

Article  CAS  Google Scholar 

Keenan TE, Tolaney SM (2020) Role of immunotherapy in triple-negative breast cancer. J Natl Compr Canc Netw 18(4):479–489

Article  CAS  Google Scholar 

Rizzo A, Ricci AD (2022) Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond. Expert Opin Investig Drugs 31(6):549–555

Article  CAS  Google Scholar 

Rizzo A, Ricci AD, Lanotte L, Lombardi L, Di Federico A, Brandi G et al (2022) Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects. Expert Opin Investig Drugs 31(6):557–565

Article  CAS  Google Scholar 

Massafra R, Bove S, La Forgia D, Comes MC, Didonna V, Gatta G et al (2022) An invasive disease event-free survival analysis to investigate Ki67 role with respect to breast cancer patients’ age: a retrospective cohort study. Cancers (Basel) 14(9):2215

Article  CAS  Google Scholar 

Rizzo A, Cusmai A, Acquafredda S, Rinaldi L, Palmiotti G (2022) Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential. Expert Opin Investig Drugs 31(6):495–498

Article  CAS  Google Scholar 

Pantelidou C, Sonzogni O, De Oliveria TM, Mehta AK, Kothari A, Wang D et al (2019) PARP inhibitor efficacy depends on CD8+ T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov 9(6):722–737

Article  Google Scholar 

Eikesdal HP, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix ES et al (2021) Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Ann Oncol 32(2):240–249

Article  CAS  Google Scholar 

Topçul M, Çeti NİL, ÖzbaşTuran S, KolusayinOzar MÖ (2018) In vitro cytotoxic effect of PARP inhibitor alone and in combination with nab-paclitaxel on triple-negative and luminal A breast cancer cells. Oncol Rep 40(1):527–535

Google Scholar 

D’Andrea AD (2018) Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair (Amst) 71:172–176

Article  CAS  Google Scholar 

Sonnenblick A, de Azambuja E, Azim HA Jr, Piccart M (2015) An update on PARP inhibitors–moving to the adjuvant setting. Nat Rev Clin Oncol 12(1):27–41

Article  CAS  Google Scholar 

Diéras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP et al (2020) Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21(10):1269–1282

Article  Google Scholar 

Loibl S, O’Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD et al (2018) Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol 19(4):497–509

Article  CAS  Google Scholar 

Rugo HS, Olopade OI, DeMichele A, Yau C, Van’t Veer LJ, Buxton MB et al (2016) Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med 375(1):23–34

Article  CAS  Google Scholar 

Kummar S, Wade JL, Oza AM, Sullivan D, Chen AP, Gandara DR et al (2016) Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Invest New Drugs 34(3):355–363

Article  CAS  Google Scholar 

O’Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C et al (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364(3):205–214

Article  CAS  Google Scholar 

O’Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M et al (2014) Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol 32(34):3840–3847

Article  CAS  Google Scholar 

Llombart-Cussac A, Bermejo B, Villanueva C, Delaloge S, Morales S, Balmaña J et al (2015) SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer. Breast Cancer Res Treat 154(2):351–357

Article  CAS  Google Scholar 

Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12

Article  CAS  Google Scholar 

Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A (2011) GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 64(4):380–382

Article  Google Scholar 

Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH et al (2018) Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379(8):753–763

Article  CAS  Google Scholar 

Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N et al (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377(6):523–533

Article  CAS  Google Scholar 

Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P et al (2018) Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med 24(5):628–637

Article  CAS  Google Scholar 

Hashimoto K, Tamura K (2010) Breakthrough breast cancer treatment-PARP inhibitor, BRCA, and triple negative breast cancer. Gan To Kagaku Ryoho 37(7):1187–1191

Google Scholar 

Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM et al (2015) Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 33(1):13–21

Article  CAS  Google Scholar